Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 1
1986 1
1988 2
1994 1
1996 1
1999 1
2000 1
2002 1
2003 1
2007 1
2009 2
2010 1
2013 2
2014 1
2015 2
2017 3
2018 1
2020 2
2022 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

25 results

Results by year

Filters applied: . Clear all
Page 1
Adult T-Cell Leukemia/Lymphoma.
Mehta-Shah N, Ratner L, Horwitz SM. Mehta-Shah N, et al. J Oncol Pract. 2017 Aug;13(8):487-492. doi: 10.1200/JOP.2017.021907. J Oncol Pract. 2017. PMID: 28796966 Free PMC article. Review.
Adult T-cell lymphoma/leukemia (ATL) is a rare T-cell lymphoproliferative neoplasm caused by human T-lymphotrophic virus 1. In its more common, aggressive forms, ATL carries one of the poorest prognoses of the non-Hodgkin lymphomas. The disease has …
Adult T-cell lymphoma/leukemia (ATL) is a rare T-cell lymphoproliferative neoplasm caused by human T-lymphotroph …
Cutaneous T-cell lymphoma/leukemia.
Siegel RS, Kuzel TM. Siegel RS, et al. Curr Treat Options Oncol. 2000 Apr;1(1):43-50. doi: 10.1007/s11864-000-0014-0. Curr Treat Options Oncol. 2000. PMID: 12057060 Review.
Careful clinical and pathologic evaluation in centers familiar with the diverse forms of CTCL is most valuable for determining treatment options. The goals of treatment in mycosis fungoides (MF), which afflicts more than 50% of patients with CTCL, are the relief of symptom …
Careful clinical and pathologic evaluation in centers familiar with the diverse forms of CTCL is most valuable for determining treatm …
Treatment of aggressive T-cell lymphoma/leukemia with anti-CD4 CAR T cells.
Feng J, Xu H, Cinquina A, Wu Z, Zhang W, Sun L, Chen Q, Tian L, Song L, Pinz KG, Wada M, Jiang X, Hanes WM, Ma Y, Zhang H. Feng J, et al. Front Immunol. 2022 Sep 12;13:997482. doi: 10.3389/fimmu.2022.997482. eCollection 2022. Front Immunol. 2022. PMID: 36172388 Free PMC article.
Additionally, CD4-IL15/IL15sushi CAR out-performed CD4 CAR in in vivo models, demonstrating a benefit to IL-15/IL-15sushi inclusion. In a Phase I clinical trial, CD4-IL15/IL15sushi CAR T cells were tested for safety in three patients with different T-cell lymphomas. …
Additionally, CD4-IL15/IL15sushi CAR out-performed CD4 CAR in in vivo models, demonstrating a benefit to IL-15/IL-15sushi inclusion. In a Ph …
Clinical Characteristics and Outcomes of Caribbean Patients With Adult T-Cell Lymphoma/Leukemia at Two Affiliated New York City Hospitals.
Chiu E, Samra B, Tam E, Baseri B, Lin B, Luhrs C, Gonsky J, Sawas A, Taiwo E, Sidhu G. Chiu E, et al. JCO Glob Oncol. 2020 Apr;6:548-556. doi: 10.1200/JGO.19.00208. JCO Glob Oncol. 2020. PMID: 32243210 Free PMC article.
PURPOSE: Adult T-cell lymphoma/leukemia (ATL) is a rare and aggressive peripheral T-cell malignancy caused by human T-cell lymphotropic virus-1 infection, which occurs in areas of high prevalence, predominantly in Japan and the Caribbean basin. ...
PURPOSE: Adult T-cell lymphoma/leukemia (ATL) is a rare and aggressive peripheral T-cell malignancy caused by hu …
Early administration of lenalidomide after allogeneic hematopoietic stem cell transplantation suppresses graft-versus-host disease by inhibiting T-cell migration to the gastrointestinal tract.
Tsubokura Y, Yoshimura H, Satake A, Nasa Y, Tsuji R, Ito T, Nomura S. Tsubokura Y, et al. Immun Inflamm Dis. 2022 Sep;10(9):e688. doi: 10.1002/iid3.688. Immun Inflamm Dis. 2022. PMID: 36039651 Free PMC article.
Lenalidomide (LEN) is an immunomodulatory drug used for treating several hematological malignancies such as multiple myeloma, adult T-cell lymphoma/leukemia, and follicular lymphoma. However, the impact of LEN on immune responses after aHSCT has not be …
Lenalidomide (LEN) is an immunomodulatory drug used for treating several hematological malignancies such as multiple myeloma, adult T …
Comorbidity between HTLV-1-associated adult T-cell lymphoma/leukemia and verrucous carcinoma: a case report.
Valencia M, Moreno L. Valencia M, et al. Colomb Med (Cali). 2017 Mar 30;48(1):35-38. Colomb Med (Cali). 2017. PMID: 28559645 Free PMC article.
However, the patient had a relapse and died before the second cycle. CLINICAL RELEVANCE: Comorbidity could lead to the associated risk factors model. ...
However, the patient had a relapse and died before the second cycle. CLINICAL RELEVANCE: Comorbidity could lead to the associated ris …
Histone deacetylase inhibitors downregulate CCR4 expression and decrease mogamulizumab efficacy in CCR4-positive mature T-cell lymphomas.
Kitadate A, Ikeda S, Abe F, Takahashi N, Shimizu N, Matsue K, Tagawa H. Kitadate A, et al. Haematologica. 2018 Jan;103(1):126-135. doi: 10.3324/haematol.2017.177279. Epub 2017 Oct 12. Haematologica. 2018. PMID: 29025909 Free PMC article.
Histone deacetylase inhibitors are promising agents for various T-cell lymphomas, including cutaneous T-cell lymphoma, peripheral T-cell lymphoma, and adult T-cell lymphoma/leukemia. CCR4 is an important therapeutic target molecule because mogamulizuma …
Histone deacetylase inhibitors are promising agents for various T-cell lymphomas, including cutaneous T-cell lymphoma, peripheral T-cell lym …
18F-fluorodeoxyglucose positron emission tomography in the staging and prognosis of T cell lymphoma.
Casulo C, Schöder H, Feeney J, Lim R, Maragulia J, Zelenetz AD, Horwitz S. Casulo C, et al. Leuk Lymphoma. 2013 Oct;54(10):2163-7. doi: 10.3109/10428194.2013.767901. Epub 2013 Mar 4. Leuk Lymphoma. 2013. PMID: 23369041 Free PMC article.
The frequency of specific T cell histologies included in this analysis were: PTCL not otherwise specified (NOS) (n = 35); angioimmunoblastic T cell lymphoma (AITL) (n = 17); anaplastic large cell lymphoma (ALCL), ALK-1+ (n = 11) and ALK-1- (n = 12); adult T cell …
The frequency of specific T cell histologies included in this analysis were: PTCL not otherwise specified (NOS) (n = 35); angioimmunoblastic …
Major prognostic factors of adult patients with advanced T-cell lymphoma/leukemia.
Shimoyama M, Ota K, Kikuchi M, Yunoki K, Konda S, Takatsuki K, Ichimaru M, Tominaga S, Tsugane S, Minato K, et al. Shimoyama M, et al. J Clin Oncol. 1988 Jul;6(7):1088-97. doi: 10.1200/JCO.1988.6.7.1088. J Clin Oncol. 1988. PMID: 2899140 Clinical Trial.
Eighty-one adult patients with advanced T-cell lymphoma/leukemia including 54 with adult T-cell leukemia/lymphoma (ATL), who were treated between 1981 and 1983 with vincristine, cyclophosphamide, prednisolone, and doxorubicin (VEPA) or VEPA plus methot …
Eighty-one adult patients with advanced T-cell lymphoma/leukemia including 54 with adult T-cell leukemia/lymphom …
Deoxycoformycin (pentostatin): clinical pharmacology, role in the chemotherapy of cancer, and use in other diseases.
Spiers AS. Spiers AS. Haematologia (Budap). 1996;27(2):55-84. Haematologia (Budap). 1996. PMID: 14651224 Review.
Pentostatin has since been shown to possess activity in chronic lymphocytic leukemia, prolymphocytic leukemia, cutaneous T-cell lymphomas, adult T-cell lymphoma-leukemia, and low grade non-Hodgkin's lymphomas. ...Aside from its use as an antineoplastic …
Pentostatin has since been shown to possess activity in chronic lymphocytic leukemia, prolymphocytic leukemia, cutaneous T-cell lymphomas, a …
25 results